Candel Therapeutics (CADL) Accounts Payables (2020 - 2025)

Candel Therapeutics has disclosed Accounts Payables across 6 years of filings, most recently posting $1.1 million for Q4 2025.

• Accounts Payables for Q4 2025 came in at $1.1 million, up 376.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.1 million (up 376.37% YoY), and the FY2025 annual result was $1.1 million, up 376.37% from the prior year.
• Accounts Payables came in at $1.1 million for Q4 2025 at Candel Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.0 million in Q2 2025 to a low of $237000.0 in Q4 2024.
• The 5-year median for Accounts Payables is $759000.0 (2021), against an average of $828210.5.
• Across the five-year window, Accounts Payables tumbled 76.1% in 2022 and soared 376.37% in 2025, its largest moves.
• Candel Therapeutics' Accounts Payables stood at $1.6 million in 2021, then sank by 76.1% to $380000.0 in 2022, then increased by 11.05% to $422000.0 in 2023, then tumbled by 43.84% to $237000.0 in 2024, then jumped by 376.37% to $1.1 million in 2025.
• The last three Accounts Payables figures came in at $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.